NCT06631092 2026-02-20Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerNEC Bio B.VPhase 1/2 Recruiting12 enrolled
NCT05799144 2025-10-22pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerVanderbilt-Ingram Cancer CenterPhase 2 Recruiting54 enrolled